PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

 PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata

Published: Mar 5, 2021 | Tags: Eli Lilly and Incyte, Report, Results, Olumiant (baricitinib), P-III, BRAVE-AA2, Study, Severe, Alopecia Areata

Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan

Published: Mar 5, 2021 | Tags: Takeda, Reports, NDA, Submission, Import, Distribute, Moderna, mRNA-1273, Japan

Roche’s Actemra/RoActemra (tocilizumab) Receives the US FDA’s Approval as the First Biologic for Systemic Sclerosis-Associated Interstitial Lung Disease

Published: Mar 5, 2021 | Tags: Roche, Actemra/RoActemra (tocilizumab), Receives, US, FDA, Approval, First, Biologic, Systemic Sclerosis-Associated Interstitial Lung Disease

Agilent to Acquire Resolution Bioscience for $695M

Published: Mar 5, 2021 | Tags: Agilent, Acquire, Resolution Bioscience, $695M

Lilly Reports Results of Tirzepatide in P-lll SURPASS-2 Trial for Type-2 Diabetes

Published: Mar 5, 2021 | Tags: Lilly, Reports, Results, Tirzepatide, P-lll, SURPASS-2, Trial, Type-2 Diabetes

Amgen to Acquire Five Prime for ~$1.9B

Published: Mar 5, 2021 | Tags: Amgen, Acquire, Five Prime, ~$1.9B

Vir and GSK Provide Update on ACTIV-3 Trial of VIR-7831 in Hospitalized Adults with COVID-19

Published: Mar 4, 2021 | Tags: Vir and GSK, Provide, Update, ACTIV-3, Trial, VIR-7831, Hospitalized Adults, COVID-19

Roche Collaborates with Tempest to Evaluate TPST-1120 in a Combination Study as 1L Treatment for Hepatocellular Carcinoma

Published: Mar 4, 2021 | Tags: Roche, Collaborates, Tempest, Evaluate, TPST-1120, Combination, Study, 1L, Treatment, Hepatocellular Carcinoma

Regeneron and Sanofi Report the US FDA’s Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children

Published: Mar 4, 2021 | Tags: Regeneron and Sanofi, Report, US, FDA, Acceptance, sBLA, Review, Dupixent, Treat, Moderate-to-Severe, Asthma, Children

Pfizer’s Lorbrena (lorlatinib) Receives FDA’s Approval for Expanding its Indication to Treat ALK-Positive Metastatic Lung Cancer

Published: Mar 4, 2021 | Tags: Pfizer, Lorbrena (lorlatinib), Receives, FDA, Approval, Expanding,  Indication, Treat, ALK-Positive Metastatic, Lung Cancer

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Published: Mar 4, 2021 | Tags: Takeda, Signs, Exclusive, License, Agreement, Ovid, Soticlestat, Treat Dravet Syndrome, Lennox-Gastaut Syndrome

Boston Scientific Signs an Agreement with BPEA to Acquire Lumenis’ Surgical Business

Published: Mar 4, 2021 | Tags: Boston Scientific, Signs, Agreement, BPEA, Acquire, Lumenis, Surgical Business

Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

Published: Mar 3, 2021 | Tags: Amgen, Reports, Results, Blincyto (blinatumomab), P-III, Study, Relapsed Acute Lymphoblastic Leukemia, Pediatric, Patients

BeiGene’s Brukinsa (zanubrutinib) Receives Health Canada’s Approval for Waldenström’s Macroglobulinemia

Published: Mar 3, 2021 | Tags: BeiGene, Brukinsa (zanubrutinib), Receives, Health Canada, Approval, Waldenström’s Macroglobulinemia

Fusion to Acquire Ipsen’s IPN-1087 to Expand its Pipeline of Radiopharmaceuticals

Published: Mar 3, 2021 | Tags: Fusion, Acquire, Ipsen, IPN-1087, Expand, Pipeline,  Radiopharmaceuticals

G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

Published: Mar 3, 2021 | Tags: G1 Therapeutics and Boehringer Ingelheim, Launch, Cosela (trilaciclib), US

Biocon Biologics and Viatris Receive CHMP’s Positive Opinion for Abevmy (biosimilar, bevacizumab)

Published: Mar 3, 2021 | Tags: Biocon Biologics and Viatris, Receive, CHMP, Positive Opinion, Abevmy (biosimilar, bevacizumab)

AbbVie Signs a Purchase Right Agreement to Acquire Mitokinin

Published: Mar 3, 2021 | Tags: AbbVie, Signs, Purchase, Right, Agreement, Acquire, Mitokinin

Veru to Advance VERU-111 in P-III Study for COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Published: Mar 2, 2021 | Tags: Veru, Advance, VERU-111, P-III, Study, COVID-19, Patients, High Risk, Acute Respiratory Distress Syndrome

AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

Published: Mar 2, 2021 | Tags: AstraZeneca, Collaborates, Junshi, Commercialize, Toripalimab, China

Hologic to Acquire Diagenode for ~$159M

Published: Mar 2, 2021 | Tags: Hologic, Acquire, Diagenode, ~$159M

Samsung Bioepis Initiates P-I Study of SB17 Proposed Biosimilar to Stelara (ustekinumab)

Published: Mar 2, 2021 | Tags: Samsung Bioepis, Initiates, P-I, Study, SB17, Proposed, Biosimilar, Stelara (ustekinumab)

Merck Reports the US FDA’s Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough

Published: Mar 2, 2021 | Tags: Merck, Reports, US, FDA, Acceptance, NDA, Review, Gefapixant, Treat, Unexplained, Chronic Cough

Merck KGaA Sign an Exclusive Worldwide License Agreement with Debiopharm for Xevinapant

Published: Mar 2, 2021 | Tags: Merck KGaA, Sign, Exclusive, Worldwide, License, Agreement, Debiopharm, Xevinapant

BMS’ Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP’s Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

Published: Mar 1, 2021 | Tags: BMS, Opdivo (nivolumab), Cabometyx (cabozantinib), Receive, CHMP, Positive Opinion, 1L, Treatment, Advanced Renal Cell Carcinoma

Regeneron’s Ab Cocktail (casirivimab + imdevimab) Receives the CHMP’s Positive Opinion to Treat COVID-19

Published: Mar 1, 2021 | Tags: Regeneron, Ab Cocktail (casirivimab + imdevimab), Receives, CHMP, Positive, Opinion, Treat, COVID-19

Johnson & Johnson Receives the US FDA’s EUA for COVID-19 Vaccine

Published: Mar 1, 2021 | Tags: Johnson & Johnson, Receives, US, FDA, EUA, COVID-19, Vaccine

AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR Trial for Severe Asthma

Published: Mar 1, 2021 | Tags: AstraZeneca and Amgen, Report, Results, Tezepelumab, P-III, NAVIGATOR, Trial, Severe Asthma

Roivant to Acquire Silicon Therapeutics for ~$450M

Published: Mar 1, 2021 | Tags: Roivant, Acquire, Silicon Therapeutics, ~$450M

BridgeBio and Origin’s Nulibry (fosdenopterin) Receives the US FDA’s Approval as the First Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Published: Mar 1, 2021 | Tags: BridgeBio and Origin, Nulibry (fosdenopterin), Receives, US, FDA, Approval, First, Therapy, Reduce, Risk, Mortality, Patients, MoCD Type A

Related Post: PharmaShots Weekly Snapshots (Feb 22- 26, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post